KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 5.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 103,530 shares of the specialty pharmaceutical company’s stock after buying an additional 4,983 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.21% of KalVista Pharmaceuticals worth $1,195,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in KalVista Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after buying an additional 104,716 shares in the last quarter. Schroder Investment Management Group grew its position in shares of KalVista Pharmaceuticals by 86.8% during the 4th quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after acquiring an additional 374,213 shares during the period. Wellington Management Group LLP increased its stake in shares of KalVista Pharmaceuticals by 4.2% in the 4th quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company’s stock valued at $1,041,000 after purchasing an additional 4,940 shares in the last quarter. Martin Worley Group acquired a new position in KalVista Pharmaceuticals in the 4th quarter worth about $86,000. Finally, Wells Fargo & Company MN boosted its position in KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company’s stock worth $171,000 after purchasing an additional 4,543 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently commented on KALV shares. Leerink Partners boosted their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, July 7th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright upped their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. Finally, JMP Securities increased their price objective on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a “market outperform” rating in a report on Tuesday, July 8th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $26.29.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $13.63 on Friday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.32. The firm has a market capitalization of $680.82 million, a PE ratio of -3.69 and a beta of -0.04. The business’s 50 day moving average price is $13.40 and its 200-day moving average price is $11.86.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the prior year, the business earned ($1.07) EPS. As a group, analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 32,979 shares of the company’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the sale, the chief executive officer owned 369,595 shares of the company’s stock, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider directly owned 106,611 shares in the company, valued at $1,262,274.24. This trade represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,878 shares of company stock worth $723,617 over the last 90 days. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).